Atazanavir metabolite summary
| Analyte | Time | Phase I Transformation | ESI(+) m/z | HLM | CYP3A4 | CYP3A5 | In Vivo |
|---|---|---|---|---|---|---|---|
| min | |||||||
| Atazanavir | 18.0 | None | 705.4 → 168.1 | Y | Y | Y | Y |
| M1 | 16.9 | MO | 721.4 → 168.1 | Y | Y | Y | Y |
| M2 | 17.1 | MO | 721.4 → 168.1 | Y | Y | Y | Y |
| M3 | 17.6 | MO | 721.4 → 168.1 | Y | Y | Y | Y |
| M4 | 18.1 | MO | 721.4 → 168.1 | Y | Y | N.D. | Y |
| M5 | 14.6 | O-Decarb | 647.4 → 168.1 | Y | Y | Y | Y |
| M6 | 14.7 | O-Decarb | 647.4 → 168.1 | Y | Y | Y (t) | Y |
| M7 | 18.0 | O-Deh | 703.4 → 168.1 | Y | Y | Y | Y |
| M8 | 17.2 | O-Deh | 703.4 → 168.1 | Y | N.D. | N.D. | Y |
| M9 | 17.9 | MO + O-Decarb | 663.4 → 168.1 | Y (t) | Y | Y | Y |
| M10 | 12.4 | MO + O-Decarb | 663.4 → 168.1 | Y | N.D. | N.D. | N.D. |
| M11 | 12.8 | MO + O-Decarb | 663.4 → 168.1 | Y | N.D. | N.D. | N.D. |
| M12 | 13.9 | MO + O-Decarb | 663.4 → 168.1 | Y | N.D. | N.D. | N.D. |
| M13 | 15.0 | DO | 737.4 → 168.1 | Y | N.D. | N.D. | N.D. |
| M14 | 16.0 | DO | 737.4 → 168.1 | Y (t) | N.D. | N.D. | N.D. |
| M15 | 16.4 | DO | 737.4 → 168.1 | Y | Y (t) | Y (t) | N.D. |
| M16 | 16.9 | DO | 737.4 → 168.1 | Y | N.D. | N.D. | N.D. |
ESI(+), electrospray ionization positive ion mode; Y, detected; MO, monooxidation; O-Decarb, oxidative decarboxylation; O-Deh, oxidative dehydration; DO, deoxidation; (t), trace amount observed; N.D., not detected.